Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
about
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerNeoadjuvant nab-paclitaxel in the treatment of breast cancerPathologic Evaluation of Breast Cancer after Neoadjuvant TherapyHow to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancerRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerRecommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Neoadjuvant therapy in the treatment of breast cancerPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerDiffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.Translating neoadjuvant therapy into survival benefits: one size does not fit all.A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsA priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative UltrasoundUltrasound imaging of breast tumor perfusion and neovascular morphology.Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Ultrasonic spectrum analysis for in vivo characterization of tumor microstructural changes in the evaluation of tumor response to chemotherapy using diagnostic ultrasound.Targeted androgen pathway suppression in localized prostate cancer: a pilot study.Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challengeIntratumor mapping of intracellular water lifetime: metabolic images of breast cancer?National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary reportPredictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.Critically short telomeres and toxicity of chemotherapy in early breast cancerTumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast CancerUsefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerImmune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy.Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patientsDual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting.Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.A program to identify prognostic and predictive gene signatures
P2860
Q24597847-EFEC6F13-162A-4891-AFA2-1D2951858118Q26748822-5EAB2F1D-3477-401D-ABE0-49313620757DQ26749261-0F8B2F7F-ED45-429A-870E-2AC8C1496B21Q26798419-84CDFB4B-E8F2-48B2-BA81-7A981645EE12Q27028084-1202AEF0-B82A-47B2-BA06-6FCDD112D96EQ27304609-0BDDB454-43B0-4605-AFBA-49F2BD403133Q27694514-31C08ADB-97D8-4DE1-BFB1-0319C6131C3DQ28240692-45FE99BF-70AD-4E2A-B512-F9B495C894ECQ28710339-734C22CF-AEC3-4766-9AC3-A8DF60757AF2Q30251738-5C0E65EE-45B0-4E8A-BB4B-AF315CCAF3A4Q30253017-08500C48-36FA-4007-8170-5A3A94EE0FE3Q30358741-5A12D83C-3C40-43C9-848C-7BDC088914CAQ30375552-DA8FA6D7-CF3B-4A8E-A694-079E17F0A55AQ30433483-1E71F10B-C791-4418-B1B3-E05548E7BE7DQ30452720-ECE047DB-477F-41AA-AC63-F840AF41A5CAQ30563985-F18365DC-AE7F-4D4D-A15B-DA7E73785089Q30810438-E69E5ED0-F4E8-4976-A898-79DA1AFA5FE2Q30814598-56084FEA-4785-4106-ABE0-77C22ED71E22Q31150366-392212F1-E77F-421B-9CB1-CCAB4A4208B2Q33416887-11B3B299-5675-44A7-AB80-D2A223A3775FQ33579853-6A27049C-B44F-4FFA-B88D-C12A0ED28B4BQ33584033-674AC9BA-ADCC-46BE-8F08-09992CD42091Q33591567-A4276810-5128-4EBF-AFF7-5F0335E8CE20Q33614238-B24E4333-5E5C-468E-9EC6-26ADC1222588Q33670107-F328FAFB-52E4-4478-859B-25E664B8F9B6Q33684080-3F0DBB02-E1BE-4C6A-82A7-3598F49B3FFAQ33712476-303E2DD2-8C6C-41BD-BB27-B6111CB392B7Q33750803-595E0F83-C85E-479E-9E33-A4BBB5FF798FQ33769821-BAEE3718-78DF-422D-8308-D0D15FDFA234Q33813431-D030C9CD-1F11-496F-A448-3EBB5CC04D5FQ33843830-2941CFEF-13B6-41C9-8CB9-B7863EA09841Q33876719-83AD3FC9-E13F-4FB4-A38A-8CF5C0496523Q33913615-6A395331-6BA2-47E1-99BE-0F921B32C2C0Q33947907-65441152-0DB5-4471-8FBE-95C1B9C7AA55Q33972737-9C04DC42-EC63-4E0B-BD9E-F7BF6BF713DCQ33973172-7A1341F2-8E7D-4361-824A-A21E8C43D1D7Q33996547-30F09782-BF2D-4806-A60B-7E0D7E7FAB03Q34050338-8C33AEA5-F2B3-49F8-B390-A7E09C970DB7Q34075789-3D8522A8-E673-4391-A41E-219689DAA728Q34105960-CAA1F317-5000-48A2-84D9-BAC95F4EE5B6
P2860
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Measurement of residual breast ...... fter neoadjuvant chemotherapy.
@en
Measurement of residual breast ...... fter neoadjuvant chemotherapy.
@nl
type
label
Measurement of residual breast ...... fter neoadjuvant chemotherapy.
@en
Measurement of residual breast ...... fter neoadjuvant chemotherapy.
@nl
prefLabel
Measurement of residual breast ...... fter neoadjuvant chemotherapy.
@en
Measurement of residual breast ...... fter neoadjuvant chemotherapy.
@nl
P2093
P356
P1476
Measurement of residual breast ...... after neoadjuvant chemotherapy
@en
P2093
Aman U Buzdar
Anna Poniecka
Bryan Hennessy
Florentia Peintinger
Gabriel N Hortobagyi
Henry Kuerer
Lajos Pusztai
Lina Assad
Marjorie Green
Radhika Rajan
P304
P356
10.1200/JCO.2007.10.6823
P407
P577
2007-09-04T00:00:00Z